Breast Cancer Tissue: Inflammatory breast cancer (IBC)

NCT05243641: Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

NCT05243641
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MET, HER2
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with HER2-negative breast cancer are eligible for phase 2
Exclusions: Patients with unstable and symptomatic brain metastasis – see trial for details
https://ClinicalTrials.gov/show/NCT05243641

NCT05198843: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

NCT05198843
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have metastases accessible for biopsy
Exclusions: Patients without one standard regimen exposure in a metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05198843

Up ↑